Corteva, Inc.'s 10-K, read.

Corteva is a large agriculture company, but its latest filings show a weaker position than the annual report suggested. Operating cash flow was negative $3.3 billion in the first half of 2026, short-term borrowings rose sharply, and the October 2026 spin-off of the seed business to Vylor coincided with a court order restricting dividends and buybacks, which was issued and then stayed pending appeal. Pending litigation and a large restructuring program add to the uncertainty.

• A temporary restraining order from 15 states and one sovereign, issued October 9, 2026, barred dividends and share repurchases pending appeal. The order is stayed for now, but the company told the court it would not pay dividends or buy back shares while the appeal is pending.
• Operating cash flow from continuing operations was negative $3.3 billion for the six months ended June 30, 2026, driven by a $1.1 billion pension and OPEB contribution, the Bayer resolution payment, and the FMC rimisoxafen prepayment. Deferred revenue fell by about $3.2 billion over the period.
• Short-term borrowings rose to $3.2 billion at June 30, 2026, from $0.9 billion at year-end 2025, and total debt rose to $4.9 billion from $2.6 billion. Cash and marketable securities fell to $2.4 billion.
• The Separation of the seed business into Vylor, completed October 1, 2026, changes the company's portfolio. Corteva keeps the Crop Protection business, which saw Q2 2026 sales decline and has an ongoing restructuring program with total pre-tax charges of $750 million to $815 million.
• Exchange offers completed October 1, 2026 retired large amounts of EIDP senior notes, with only about $65 million of the 2030 notes, $24 million of the 2032 notes, and $72 million of the 2033 notes still outstanding. The change in the debt structure and the consent-based indenture amendments add uncertainty around the capital structure.

Not investment advice — general research, the same for every reader. You make your own calls.